September 5, 2019 / 11:19 AM / 5 months ago

GSK urges U.S. court to revive $235 million patent verdict against Teva

A federal appeals court appeared divided during oral argument on Wednesday over whether to resurrect a jury verdict that required Teva Pharmaceutical Industries Ltd to pay GlaxoSmithKline PLC more than $235 million for infringing a patent covering its blood pressure drug Coreg.

A three-judge panel of the U.S. Court of Appeals for the Federal Circuit heard oral arguments in GSK’s appeal of a post-trial ruling that vacated the 2017 verdict.

To read the full story on Westlaw Practitioner Insights, click here:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below